Award

GLO-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell non-Hodgkin Lymphoma.

  • THE UNIVERSITY OF BIRMINGHAM

F15: Voluntary ex ante transparency notice

Notice identifier: 2022/S 000-018410

Procurement identifier (OCID): ocds-h6vhtk-034e92

Published 5 July 2022, 4:47pm



Section one: Contracting authority/entity

one.1) Name and addresses

THE UNIVERSITY OF BIRMINGHAM

Chancellors Close

BIRMINGHAM

B152TT

Contact

Karen Aird

Email

k.aird@bham.ac.uk

Telephone

+44 1214158491

Country

United Kingdom

NUTS code

UKG31 - Birmingham

Internet address(es)

Main address

https://www.birmingham.ac.uk/index.aspx

one.4) Type of the contracting authority

Body governed by public law

one.5) Main activity

Education


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

GLO-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell non-Hodgkin Lymphoma.

Reference number

SC10895/22

two.1.2) Main CPV code

  • 48611000 - Database software package

two.1.3) Type of contract

Supplies

two.1.4) Short description

The GLO-BNHL trial (sponsored by the University of Birmingham) is a platform study which is funded by industry collaborators and Cancer Research UK. The trial is required to have a suitably compliant clinical trial database (electronic data capture (EDC) system) that is active and ready for use by September 2022. Funding is provided to support the trial to be compliant with additional regulations (International Conference on Harmonization, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards - specifically 21 CFR Part 11 guidance.

two.1.6) Information about lots

This contract is divided into lots: No

two.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £587,644.28

two.2) Description

two.2.2) Additional CPV code(s)

  • 48610000 - Database systems
  • 48620000 - Operating systems

two.2.3) Place of performance

NUTS codes
  • UKG - West Midlands (England)

two.2.4) Description of the procurement

The GLO-BNHL trial (sponsored by the University of Birmingham) is a platform study which is funded by industry collaborators and Cancer Research UK. The trial is required to have a suitably compliant clinical trial database (electronic data capture (EDC) system) that is active and ready for use by September 2022. Funding is provided to support the trial to be compliant with additional regulations (International Conference on Harmonization, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) standards - specifically 21 CFR Part 11 guidance.

two.2.11) Information about options

Options: No


Section four. Procedure

four.1) Description

four.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

  • The procurement falls outside the scope of application of the regulations

Explanation:

Medidata Rave are an established provider of electronic remote data capture (eRDC) systems. The company has a track record of delivering clinical trial databases to 21 CFR Part 11 standards. Additionally, Medidata has undergone a detailed audit of their systems by the University of Birmingham and have successfully passed inspections by regulatory health authorities.

The industry collaborator use Medidata Rave as their database provider and as such house a Case Report Form (CRF) Library within the platform which will be used for this trial. This library is not accessible elsewhere. In addition, regular transfers of data to the industry collaborator will be required which require the same eRDC system for ease of transfer. Additionally, drug supply will be managed within the system and Medidata have established relationships with the industry partners preferred drug distributor.

The following are detailed reasons for the selection of Medidata as a vendor to provide an EDC system GLO-BNHL:

• Experience in relevant disease group

• Access to CRF library for the disease area

• Access to industry partner CRF libraries

• The same eRDC system as the funder (industry collaborator) to enable ease of data transfer

• Able to deliver a live clinical trial database for the study by September 2022

• Successfully passed a regulatory inspection and audit by the University of Birmingham

• Able to demonstrate compliance with regulations across all global regions

• Able to implement major trial protocol amendments (new treatment arms) without requiring temporarily closures or existing live aspects of the database.

• Able to manage a treatment management system with direct access to drug distributor systems

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No


Section five. Award of contract/concession

Contract No

SC10895/22

Title

GLO-BNHL: A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell non-Hodgkin Lymphoma.

A contract/lot is awarded: Yes

five.2) Award of contract/concession

five.2.1) Date of conclusion of the contract

30 June 2022

five.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

five.2.3) Name and address of the contractor/concessionaire

Medidata Solutions International Limited

London

Country

United Kingdom

NUTS code
  • UKI - London
The contractor/concessionaire is an SME

No

five.2.4) Information on value of contract/lot/concession (excluding VAT)

Initial estimated total value of the contract/lot/concession: £587,644.28

Total value of the contract/lot/concession: £587,644.28


Section six. Complementary information

six.4) Procedures for review

six.4.1) Review body

University of Birmingham

Birmingham

Country

United Kingdom